

# ForPatients

by Roche

Metastatic Solid Tumors Advanced Solid Tumors

## A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors

**Trial Status**  
Recruiting

**Trial Runs In**  
5 Countries

**Trial Identifier**  
NCT06537310 2024-512839-70-00  
BP44956

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary clinical activity of RO7567132 as single agent and in combination with atezolizumab. The study will enroll adult participants with selected locally advanced and/or metastatic solid tumors for whom standard therapy does not exist, has proven to be ineffective or intolerable, or is not acceptable to the participant.

**Hoffmann-La Roche**  
Sponsor

**Phase 1**  
Phase

---

**NCT06537310 2024-512839-70-00 BP44956**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
≥18 Years

**Healthy Volunteers**  
No

---